Balabolkin I I, Bulgakova V A
Eksp Klin Farmakol. 2016;79(11):35-40.
Data on the pharmacogenetic markers of the effectiveness of treatment of children with atopic asthma are presented, which reveal a variability of the response to treatment with glucocorticosteroids, leukotriene receptor antagonists, and b2-adrenoreceptor agonists in children with bronchial asthma. The association of genotype Gly/Glyl6 gene b2-adrenergic receptor with insufficient effect of the therapy with short-acting b2-agonists is demonstrated. The Glyl6 allele, CYP2D6 - 1934GGd contributes to the formation of a phenotype with severe asthma and tolerance to therapy with b2-agonists and inhaled corticosteroids.
本文展示了关于特应性哮喘儿童治疗有效性的药物遗传学标志物的数据，这些数据揭示了支气管哮喘儿童对糖皮质激素、白三烯受体拮抗剂和β2肾上腺素能受体激动剂治疗反应的变异性。研究证实了β2肾上腺素能受体基因Gly/Gly16基因型与短效β2激动剂治疗效果不佳之间的关联。Gly16等位基因、CYP2D6 - 1934GGd有助于形成严重哮喘以及对β2激动剂和吸入性糖皮质激素治疗耐受的表型。
